Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-KPd in High-risk Relapsed/Refractory Multiple Myeloma
NCT07015021Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Overall Response Rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07015021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015021.